Physician profile
Brett E Willden
NPI 1174515134
$3,534.91
in general payments reported to CMS, 2019-2025
30 companies · $16.54 in 2025
The $16.54 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $591 · 2020: $764 · 2021: $1,026 · 2022: $806 · 2023: $269 · 2024: $62.46 · 2025: $16.54.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $348.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $347.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $679.89 | 2019-2023 | Breztri |
| Abbvie INC. | $480.96 | 2021-2024 | Qulipta |
| Novo Nordisk INC | $387.88 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $205.83 | 2019-2022 | |
| Allergan, INC. | $172.84 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $165.60 | 2021 | |
| Amgen INC. | $160.73 | 2019-2021 | |
| Abbott Laboratories | $137.89 | 2020-2024 | Prodigy |
| Boston Scientific Corporation | $137.73 | 2020-2024 | Watchman Flx, Superion Indirect Decompression System |
| Idorsia Pharmaceuticals US INC | $135.26 | 2023 | Quviviq |
| Lilly USA, LLC | $119.53 | 2020-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $103.27 | 2019-2021 | |
| Impel Pharmaceuticals INC. | $101.37 | 2022 | |
| Merck Sharp & Dohme LLC | $71.78 | 2019-2021 | |
| Antares Pharma, INC. | $68.53 | 2020-2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nevro Corp. | $57.73 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $56.70 | 2022 | |
| Pfizer INC. | $44.50 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $42.42 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $42.18 | 2020-2021 | |
| Eisai INC. | $25.51 | 2020-2021 | |
| Ultragenyx Pharmaceutical INC. | $20.86 | 2022 | |
| Genentech USA, INC. | $19.29 | 2020 | |
| Exact Sciences Corporation | $16.54 | 2025 | The Cologuard Plus Collection Kit |
| Nestle Healthcare Nutrition INC. | $15.04 | 2023 | |
| Impulse Dynamics (USA) INC. | $13.21 | 2023 | Optimizer |
| Currax Pharmaceuticals LLC | $13.20 | 2023 | Contrave, Onzetra Xsail |
| Phadia US INC. | $13.13 | 2020 | |
| Medtronic, INC. | $13.08 | 2021 | |
| Arbor Pharmaceuticals, INC. | $12.43 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brett Willden listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.